R
Recursion Pharma
Biotech & Life Sciences · Salt Lake City, United States · Founded 2013 · IPO 2021 Unicorn
A clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery
Recursion Pharma mafia
Startups founded by Recursion Pharma alumni
Former Recursion Pharma employees who went on to start their own companies. Sorted by Dealroom signal score.
Joe Betts-LacroixUnited States
Jacob RinaldiUnited States
Zavain DarUnited States
David KartchnerUnited States
Karthik Raman, PhDUnited States
Dean Y. LiUnited States
Ian QuigleyUnited States
Daniel CohenCanadaGlobal footprint
Where Recursion Pharma has talent and traffic
(83 of 942 staff)
team presence
across markets
Patent intelligence
$13M patent portfolio · 96 active families
Where Recursion Pharma concentrates vs peers
Each axis is a top-10 topic across Recursion Pharma and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Capital deployed
Recursion Pharma's 5 investments and acquisitions.
Every disclosed deal where Recursion Pharma appeared as a backer or acquirer, 2020–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
5 deals across Recursion Pharma's capital deployment.
Where the deals concentrate by sector, stage, and decade.
01 · Deployment strategy vs peers
Where Recursion Pharma deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
02 · Portfolio market map
Recursion Pharma's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Sentiment on X
What X is saying about Recursion Pharma
An AI-synthesized read of the highest-engagement posts about Recursion Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Recursion Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.